Global Testosterone Undecanoate Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Testosterone Undecanoate Market Research Report 2024
Testosterone undecanoate, sold under the brand names Nebido, Aveed, and Andriol among others, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men. It is also used in hormone therapy for transgender men. It is taken by mouth two to three times per day with food or given by injection into muscle once every 12 weeks or so.
According to Mr Accuracy reports new survey, global Testosterone Undecanoate market is projected to reach US$ 827.4 million in 2029, increasing from US$ 564 million in 2022, with the CAGR of 6.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Testosterone Undecanoate market research.
Key manufacturers engaged in the Testosterone Undecanoate industry include Bayer AG, Endo Pharmaceuticals, Merck Sharp & Dohme, Taro Pharmaceutical, Cipla, Zhejiang Xianju Pharmaceutical and Zhejiang Medicine Co., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Testosterone Undecanoate were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Testosterone Undecanoate market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Testosterone Undecanoate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Bayer AG
Endo Pharmaceuticals
Merck Sharp & Dohme
Taro Pharmaceutical
Cipla
Zhejiang Xianju Pharmaceutical
Zhejiang Medicine Co.
Segment by Type
Injection
Oral
Primary Hypogonadism
Hypogonadotropic Hypogonadism
Late-Onset Hypogonadism
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Testosterone Undecanoate report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Testosterone Undecanoate market is projected to reach US$ 827.4 million in 2029, increasing from US$ 564 million in 2022, with the CAGR of 6.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Testosterone Undecanoate market research.
Key manufacturers engaged in the Testosterone Undecanoate industry include Bayer AG, Endo Pharmaceuticals, Merck Sharp & Dohme, Taro Pharmaceutical, Cipla, Zhejiang Xianju Pharmaceutical and Zhejiang Medicine Co., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Testosterone Undecanoate were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Testosterone Undecanoate market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Testosterone Undecanoate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bayer AG
Endo Pharmaceuticals
Merck Sharp & Dohme
Taro Pharmaceutical
Cipla
Zhejiang Xianju Pharmaceutical
Zhejiang Medicine Co.
Segment by Type
Injection
Oral
Segment by Application
Primary Hypogonadism
Hypogonadotropic Hypogonadism
Late-Onset Hypogonadism
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Testosterone Undecanoate report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source